This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly’s Weight-Loss Treatments
The Motley FoolTerns has a modest market cap of less than $800 million, and its possible upside could be massive.
Terns has a modest market cap of less than $800 million, and its possible upside could be massive.